The Under The Radar Minute  is an independent paid circulation newsletter and advertising report produced by NWBB Inc. . This paid advertising issue does not purport to provide an analysis of any company’s financial position or prospects and this is not to be construed as a recommendation by The Under The Radar Minute and is not in any way to be construed as an offer or solicitation to buy or sell any security. Although the information contained in this advertisement is believed to be reliable, The Under The Radar Minute and its editors make no warranties as to the accuracy of the description of any of the content herein and accept no liability for how readers or listeners  may choose to use it. The Under The Radar Minute, including any of our principals, officers, directors, partners, agents, or affiliates are not, nor do we represent ourselves to be, registered investment advisors, brokers, or dealers in securities. Readers and listeners should independently verify all statements made in this advertisement. Product names, logos, brands, and other trademarks featured or referred to within this presentation and on line report are the property of their respective trademark holders. These trademark holders are not affiliated with The Under The Radar Minute The radio broadcast and on line report, and the opinions of those quoted within are for informational and advertising purposes only. Speculation in securities carries a high degree of risk, and investors purchasing speculative investments should be capable of absorbing losses of all of their invested capital. There is no assurance that the featured company will receive additional funding or experience any future development necessary for corporate success. Information contained in the broadcast  and on line report contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the expected continual growth of the market for the company’s products, the company’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur. Past investment performance is not in any way indicative of future investment performance. Readers must consult with registered professional investment, taxation, and portfolio advisors before making an investment decision.  The companies or “Company” or “Companies” or “Profiled Company” or “Profiled Companies”), the company featured in this report, appears as paid advertising,
Advertisement
The Under The Radar minute is a nationally aired radio segment providing information and awareness of publicly traded companies currently “Under The Radar”
The Best 60 Seconds On Radio Devoted To Identifying Those Companies With Incredible Upside Potential
Copyright 2016 : Under The Radar minute. 
For question, comments or to suggest an article topic please contact :  Editor@UnderTheRadarMinute.com
This Company Has Recently Achieved Incredible Sales Growth Topping More Than 1,000% on Internet Retail Giant Amazon
It isn’t often that you see headline news of record sales on Amazon that exceed 1,000 percent for a relatively new and unfamiliar consumer product. But that is exactly what is happening for one small company, who’s revolutionary and innovative diabetic products continue to experience tremendous demand from consumers. Last year in FY2019 this company experienced sales growth of 224% on the Internet retail giant’s website. Earlier this year, in May 2020, that number was dwarfed by record monthly sales on Amazon up 1,048% Now, in a press release dated July 8, 2020, the company announced that its record sales numbers for the month of May have been bested by those reported for June; rising by some 1,284% year-over-year. Interest by investors also appears to be gaining momentum as the share price has recently skyrocketed over 2,000 percent from a low of around 10 cents to a price of $1.90 a share since just April of this year. Perhaps one reason for the sudden surge in sales is that this company is addressing the rather disturbing macro-trend of obesity and type-2 diabetes taking place around the world. Obesity rates in the United States have grown almost exponentially over the past 20 years, and there does not appear to be any end in sight.
Source: American Diabetes Association
Even high-profile drug-store chain CVS Health Corporation (CVS), is expanding their diabetic-care section in their new store design plans. CVS Health recently made the decision to sign a national distribution contract to carry all four SKU’s of the company’s GlucoDown® diabetic tea mix.
GlucoDown® products not only enjoy distribution at Amazon, the largest Internet retailer in the United States, but are also carried at Wal-Mart, the largest brick-and-mortar retailer in the country. GlucoDown® even enjoys the coveted Approved by Amazon Brand Registry” status on the Amazon website. This makes GlucoDown® an Amazon Registered Brand.
At Wal-Mart, the Glucodown® Peach Flavor tea mix can be found in over 1,800 stores across the country. The item is stocked on shelves in the Wal-Mart pharmacy section. The company has been in discussions to expand the distribution footprint in Wal-Mart stores to encompass all 3,500 stores nationwide. Wal-Mart also features the GlucoDown® Peach Flavor for sale on their website; Walmart.com It is no small feat for any company to land the two largest retailers in the United States as their first two distribution partners. Glucose Health, Inc. CEO, Murray Fleming, has done an exemplary job of not only building the Glucodown® brand, but also of building shareholder value in the process. 
Having these very capable and high-profile individuals in the Boardroom is definitely an asset to Mr. Fleming, as he builds on the successes that he has already achieved as the company CEO. 
One ingredient, in particular, that has been added to the current GlucoDown® formula, boasts an ancient history of being effective in combating problems associated with elevated blood sugar levels. That ingredient is called "Banaba Leaf"; not to be confused with banana leaf. Banaba Leaf has been utilized in the traditional medical system in India known as Ayurvedic for more than 2000 years. In 1940, the first clinical research observing the hypoglycemic and anti- hyperlipidemic properties of the naturally occurring corosolic acid in Banaba Leaf, was published. To learn more about Banaba Leaf and corosolic acid, please read the following clinical study sourced from the NIH website The importance of all this scientific-based data became very apparent when it came time to meet the rigorous testing standards that CVS requires, in order to gain acceptance for inclusion in their stores nationwide. The “Tested-to-be-trusted” program at CVS ensures that every product on the shelves in CVS stores has been tested for not only what it contains, but, also, for what it doesn’t contain.
In a press release, dated June 3, 2020, announcing the agreement between CVS Health Corp. and Glucose Health, Inc., it states: “CVS is a leader among pharmacy retailers in mandating independent third-party testing using the ANSI 173 standard – the only American National Standard for testing and certifying dietary supplements, maintained by NSF International. Random samples of GLUCODOWN® were provided to NSF International and the successful test results were released simultaneously to CVS and Glucose Health, Inc., on May 5, 2020.”
NSF Certification was an important milestone event for Glucose Health, Inc. inasmuch as it paves the way for possible inclusion for the company’s products among other big-name drug store retailers. The two most important factors that drive consumer acceptance of a new product are efficacy and taste. The effectiveness of GlucoDown, in helping to curb appetite and maintain healthy glucose levels, are borne out by the aforementioned 20 years of clinical research and the plethora of studies conducted on Fibersol, its main ingredient. The real test, however, when it comes to consumer acceptance, is taste. Looking at the reviews from verified purchasers on Amazon’s website, it is clear that the taste is among the reasons most often cited as to why the product resonates with consumers.   As of July 6, 2020, the following information regarding GlucoDown consumer reviews appeared on the Amazon website:  
Raspberry Flavor – 120 total reviews / rated 4.3 out of 5.0 stars
Super Berry Flavor – 128 total reviews / rated 4.4 out of 5.0 stars
This Week We Look At:    Glucose Health Inc.  A Rapidly Growing Company Within The Functional Beverage Sector
As a result, annual revenues from the sales of diabetic-related products is projected to soar over the next few decades, as well. Just take a look at this chart which shows projected spending on diabetic- care products from 2008 through 2033 in billions of dollars.
After a dramatic rise in price to $1.90, surrounding the CVS news, GLUC has settled into an area around $1.00, where it seems to have strong buying support. We should note that Mr. Fleming’s own personal net worth is directly tied to the performance of Glucose Health, Inc. share price, since he receives no salary or other cash compensation for performing the duties as CEO of the company. In fact, if investors take a look at the financial statements of the company, they will find that Glucose Health, Inc. does not even accrue a salary for Mr. Fleming. Talk about management with skin in the game! In an area of the stock market that is known for its share of less than trustworthy corporate governance, shady management deals, and capital structures that can often times see outstanding share counts in the billions, Glucose Health, Inc. stands out as one of the most reputable and uncharacteristic Pink Sheet companies to ever grace the OTC market landscape. If you want to be impressed, just take a look at the composition of the GLUC Board of Directors. The Glucose Health, Inc. Board of Directors consists of some very notable and extraordinary individuals, with extensive backgrounds in accounting, marketing, and management. Besides, CEO Murray Fleming, the current Board of Directors include Gerry David, Hal Kravitz and John Fieldly.
Gerry David was one of only 25 Gold Winners in the  prestigious 2016 CEO World Awards and was selected as “The Leader” in the CEO of the Year category In recognition of his professional achievements,
John Fieldly, who served as the CFO of Celsius Holdings, Inc. from early 2012 to March of 2018 was named the company CEO in the month of April that same year. Since, taking over as the CEO the stock of Celsius Holdings, Inc. (CELH) has tripled; rising from around $4.00 a share to almost $12.00 recently.
Hal Kravitz spent over 30 years with Coca-Cola Company; serving in various roles and holding a number of key positions within the Coke Empire. He most recently led the Glaceau business unit, which in 2007 acquired Glaceau’s Vitamin Water brand for $4.1 billion. He was also named as the CEO of AQUAhydrate in January of 2015.
With 1 in 3 in the U.S. population, some 86 million Americans, already pre-diabetic, and with 9 out of 10 not even knowing that they even have it, it is a product that clearly appears to be in the right place at the right time.
While we are on the subject of corporate governance and capital structure arrangement, let’s take a look at the extremely attractive share hierarchy. According to OTCMarkets.com, as of June 30, 2020, there are a total of 12,494,617 common shares outstanding. Of that amount, roughly half, or 6,244,745 are restricted. The remaining 6,249,872 shares are unrestricted. The public float stands at a mere 5,680,205 shares. That is among the lowest numbers that we have seen for an OTC markets company that trades on the pink sheets. In the spring of 2018, a group of angel investors began having discussions with the company CEO, regarding their concern about the high level of fixed convertible debt that was being held by a single entity. The debt, in the form of a convertible note, carried a fixed conversion price of $0.008 a share. The outstanding balance on the note was approximately $165,000 at that time. This meant that upon a full conversion of the outstanding convertible debt, from this single note, there would have been an additional 20,625,000 shares of common stock that would have to be issued to the noteholder. The consequence from this potential dilution would have been devastating to the capital structure of the company. After much discussion, an agreement was reached with the note holder to extinguish the convertible debt by paying off the note in full. This result of this was a capital raise totaling $460,000 in May of 2018. Now, that the “sword of Damocles” had effectively been removed from overhead, the company’s balance sheet looked much stronger, and the company could concentrate on moving forward with a strategic plan for expanding the GlucoDown® line of diabetic teas. Glucose Health, Inc. (GLUC) first appeared on our radar screen in early 2017, when we were looking for a pure investment play to capitalize on the growing trend of an alarming worldwide diabetes epidemic.  There were existing products on the market, from companies like Abbott Lab's (ABT) with their product called Glucerna®, as well as Boost®, which was developed and marketed by Nestle (NSRGY). While these products were widely-known, among consumers, the impact from the revenues that these products produced were so insignificant that they had no meaningful impact to the financial results of either Abbott Laboratories or Nestle. The other drawback that we saw to these two products was the fact that they were a high viscosity milk shake type drink that did not have broad appeal to the consumer marketplace. Many people do not care for a thick, dairy-like beverage, and would prefer something lighter. These dairy-like shakes are inclined to produce a film-like coating in the mouth and throat. Too often, these types of beverages result in mucous build-up as well. Surprisingly, no one had yet developed a diabetic drink that was more consumer-friendly and similar to other widely-embraced beverages like teas, coffees and sodas. Glucose Health's product, named GlucoDown®, was the first diabetic drink that had properties similar to other mainstream beverages that consumers drank regularly. The GlucoDown® product was also the first of its kind to utilize a breakthrough ingredient developed by the billion dollar food conglomerate Archer Daniels Midland Company (ADM), called Fibersol® in a tea-mix. In July of 2018, The Food & Drug Administration, concluded that "based on (its) careful review of the strength of scientific evidence" that Fibersol®-2 meets "our regulatory definition of dietary fiber" as established in 2016, in Title 21 CFR 101.9(c)(6)(i).3 Fibersol, which was developed through a joint venture between Archer Daniels Midland Company and Matsutani, LLC was subsequently granted approval status on the FDA list of dietary fibers. Another benefit of Fibersol found in these studies was that it provided an increased feeling of satiety, i.e., a feeling of being fuller faster. This satiety effect is helpful in curbing a person’s appetite so as not to overeat; a major contributing factor to obesity. One of the challenges, according to Glucose Health, Inc. CEO Murray Fleming, was to develop a process whereby the Fibersol® ingredient could be agglomerated into a low viscosity beverage like a tea. After performing extensive research on the challenges of agglomerating Fibersol® into a tea-mix, a solution was found. Numerous formulas, combining other ingredients including various vitamins and minerals, were tested before deciding on a final formula. 
“Fibersol is backed by more than 20 years of clinical research and almost 100 published studies demonstrating its physiological effects, the release said. The studies outline how the additive helps maintain intestinal regularity attenuate post-meal blood glucose levels and retain healthy post-meal serum triglycerides.”
Source: Food in Canada.
There has also been some discussion, in social media circles such as Twitter and Facebook, as to whether the COVID-19 pandemic may be creating ancillary demand for GlucoDown®, as many publications have pointed out the increased risk that individuals who face compromised health conditions face when dealing with the Coronavirus. Here are some sources, pulled from the Internet where information on the risks of Coronavirus and Diabetes are mentioned: Health.com     "What makes the coronavirus so dangerous for people with diabetes? First, because the immune system is compromised, it’s harder for the body to fight off the coronavirus, states the International Diabetes Foundation (IDF). Viruses also may thrive when blood glucose levels are high." Diatribe.org    "[High blood glucose levels challenge] the immune system, leaving the body vulnerable to severe outcomes with infections. Working with your diabetes care team to manage blood sugars would help the immune system to function properly and increase overall wellness." WebMD.com   "By following guidelines from the CDC and WHO (World Health Organization) and keeping your diabetes in good control, you may avoid contracting the virus in the first place or at least have a milder case." Myglu.org "Falling ill generally raises blood sugars and taxes the body more heavily in people with diabetes – so what can we do to prevent it?" Healthline.com “In general people with diabetes face greater risks of complications when dealing with viral infections like flu, and that is likely to be true with COVID-19,” the American Diabetes Association (ADA) said in a statement on Feb. 28."  "The fact is that people with diabetes are at higher risk when it comes to things like influenza (flu), pneumonia, and now COVID-19 because when glucose levels are fluctuating or elevated consistently, we have a lower immune response (less protection against disease), so we risk getting sicker quicker. There may also be an underlying risk of exacerbated illness simply due to having diabetes even if glucose levels are in range." In summary, this company now has everything that it needs to make it an extremely attractive candidate for micro-cap investing. Strong management, backed by a seasoned Board of Directors with a depth of experience in all relevant aspects of building a successful business enterprise. A GlucoDown® product formula, with a key ingredient backed by over 20 years of clinical research and over 100 research studies, shown to help aid in maintaining healthy glucose levels, while helping to address the macro-trend of a growing world population that suffers from obesity and type-2 diabetes. The two largest U.S. retailers, in Wal-Mart and Amazon, who have partnered with the company to distribute the GlucoDown® product line of diabetic-friendly teas.  A capital structure that has a very low public float, and no toxic debt on the balance sheet. A hard-working CEO, whose interest is clearly aligned with those of other company shareholders by virtue of his personal net worth being directly tied to increasing future shareholder value through building a prominent brand. The recent announcement that after receiving NSF certification, CVS Health Company will begin to carry all four flavors of GlucoDown® tea mix in its pharmacies nationwide beginning in the summer of 2020. Ready access to capital from a group of angel investors, who have committed themselves to supporting the continued organic growth of the company throughout the coming years. Do Your Own Research Now on Glucose Health Inc.  GLUC
Ř Ř Ř Ř Ř Ř Ř
Source: Centers for Disease Control